132 related articles for article (PubMed ID: 21656514)
1. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study.
Chavez-MacGregor M; Zhao H; Fang S; Srokowski TP; Hortobagyi GN; Giordano SH
Cancer; 2011 Aug; 117(16):3641-9. PubMed ID: 21656514
[TBL] [Abstract][Full Text] [Related]
2. Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer.
Chavez-MacGregor M; Zhao H; Kroll M; Fang S; Zhang N; Hortobagyi GN; Buchholz TA; Shih YC; Giordano SH
Ann Oncol; 2011 Nov; 22(11):2394-2402. PubMed ID: 21393379
[TBL] [Abstract][Full Text] [Related]
3. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study.
Lai Y; Ye Z; Civan JM; Wang C; Cristofanilli M; Mu Z; Austin L; Palazzo JP; Myers RE; Yang H
Breast Cancer Res Treat; 2015 Sep; 153(2):407-16. PubMed ID: 26264468
[TBL] [Abstract][Full Text] [Related]
4. Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer.
Du XL; Zhang Y; Hardy D
Cancer Causes Control; 2016 May; 27(5):695-707. PubMed ID: 27059219
[TBL] [Abstract][Full Text] [Related]
5. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.
Hershman DL; Buono DL; Malin J; McBride R; Tsai WY; Neugut AI
J Natl Cancer Inst; 2009 Dec; 101(23):1633-41. PubMed ID: 19903808
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
Rosenstock AS; Niu J; Giordano SH; Zhao H; Wolff AC; Chavez-MacGregor M
Cancer; 2018 Mar; 124(5):899-906. PubMed ID: 29236294
[TBL] [Abstract][Full Text] [Related]
7. Use of Hematopoietic Growth Factors and Risk of Thromboembolic and Pulmonary Toxicities in Elderly Patients with Advanced Ovarian Cancer.
Poonawalla IB; Piller LB; Lairson DR; Chan W; Du XL
Womens Health Issues; 2016; 26(5):574-83. PubMed ID: 27365286
[TBL] [Abstract][Full Text] [Related]
8. The Impact of the Risk Evaluation Mitigation Strategy for Erythropoiesis-Stimulating Agents on Their Use and the Incidence of Stroke in Medicare Subjects with Chemotherapy-Induced Anemia with Lung and/or Breast Cancers.
Hollingsworth K; Romney MC; Crawford A; McAna J
Popul Health Manag; 2016 Feb; 19(1):63-9. PubMed ID: 26102512
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
10. Are venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly? A case-control study of Medicare beneficiaries.
Polite BN; Lamont EB
Cancer; 2006 Feb; 106(4):923-30. PubMed ID: 16411227
[TBL] [Abstract][Full Text] [Related]
11. Risks of Venous Thromboembolism, Stroke, Heart Disease, and Myelodysplastic Syndrome Associated With Hematopoietic Growth Factors in a Large Population-Based Cohort of Patients With Colorectal Cancer.
Du XL; Zhang Y
Clin Colorectal Cancer; 2015 Dec; 14(4):e21-31. PubMed ID: 26119923
[TBL] [Abstract][Full Text] [Related]
12. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
Poorvu PD; Vaz-Luis I; Freedman RA; Lin NU; Barry WT; Winer EP; Hassett MJ
Breast Cancer Res Treat; 2018 Apr; 168(3):727-737. PubMed ID: 29332137
[TBL] [Abstract][Full Text] [Related]
13. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
14. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy.
Baxter NN; Durham SB; Phillips KA; Habermann EB; Virning BA
J Am Geriatr Soc; 2009 Mar; 57(3):403-11. PubMed ID: 19278395
[TBL] [Abstract][Full Text] [Related]
15. Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort.
Du XL; Lairson DR; Begley CE; Fang S
J Clin Oncol; 2005 Dec; 23(34):8620-8. PubMed ID: 16314624
[TBL] [Abstract][Full Text] [Related]
16. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy.
Freedman RA; Vaz-Luis I; Barry WT; Lii H; Lin NU; Winer EP; Keating NL
Breast Cancer Res Treat; 2014 Jun; 145(2):491-501. PubMed ID: 24756187
[TBL] [Abstract][Full Text] [Related]
17. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer.
Wright JD; Neugut AI; Wilde ET; Buono DL; Malin J; Tsai WY; Hershman DL
J Clin Oncol; 2011 Sep; 29(25):3408-18. PubMed ID: 21810679
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer.
Nurgalieva Z; Liu CC; Du XL
Med Oncol; 2011 Sep; 28(3):716-25. PubMed ID: 20361359
[TBL] [Abstract][Full Text] [Related]
19. Association between adjuvant chemotherapy and risk of acute kidney injury in elderly women diagnosed with early-stage breast cancer.
Li S; Liu J; Virnig BA; Collins AJ
Breast Cancer Res Treat; 2017 Feb; 161(3):515-524. PubMed ID: 27933451
[TBL] [Abstract][Full Text] [Related]
20. Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.
Griffiths RI; Lalla D; Herbert RJ; Doan JF; Brammer MG; Danese MD
Cancer Invest; 2011 Nov; 29(9):573-84. PubMed ID: 21929325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
